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Abstract
Accumulation of mutations in mitochondrial DNA (mtDNA) is thought to be responsible for
mitochondrial, and other, diseases and biological phenomena, such as diabetes, cancer,
neurodegenerative diseases, and aging. Mouse models may elucidate the relationship
between mutations in mtDNA and these abnormalities. However, because of the difficulty of
mtDNA manipulation, generation of mouse models has not sufficiently progressed to enable
such studies. To overcome this difficulty and to establish a source of diverse mtDNA muta-
tions, we here generated cultured mouse cells containing mtDNA derived from an mtDNA
mutator mouse that accumulates random mtDNA mutations with age. Mutation analysis of
the obtained transmitochondrial cytoplasmic hybrid cells (cybrids) revealed that the cells
harbored diverse mtDNA mutations occurring at a higher frequency than in mouse tissues,
and exhibited severe respiration defects that would be lethal in tissues or organs. Abnormal
respiratory complex formation and high stress on the mitochondrial protein quality control
system appeared to be involved in these severe respiration defects. The mutation rates of
the majority of highly accumulated mutations converged to either approximately 5%, 10%,
or 40%, suggesting that these mutations are linked on the respective mtDNA molecules,
and mtDNA in cybrid cells likely consisted of mtDNA molecules clonally expanded from the
small population of introduced mtDNAs. Thus, the linked mutations in these cybrid cells can-
not be evaluated individually. In addition, mtDNA mutations homologous to confirmed patho-
genic mutations in human were rarely observed in our generated cybrids. However, the
transmitochondrial cybrids constitute a useful tool for concentrating pathogenic mtDNA
mutations and as a source of diverse mtDNA mutations to elucidate the relationship
between mtDNA mutations and diseases.
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Introduction
Mitochondria produce the majority of ATP required by the body by oxidative phosphorylation
(OXPHOS). Mitochondrial DNA (mtDNA), the unique mitochondrial genome, encodes 13
polypeptides—the subunits of respiratory complexes, and rRNA and tRNA molecules needed
for translation of these polypeptides. Mutations in mtDNA result in reduced ATP production
because they lead to abnormal structure of respiratory chain subunits or reduced translation of
mitochondrial proteins, and underlie various disorders, termed mitochondrial diseases [1].
Until now, many mutations in mtDNA have been reported as candidate causative muta-
tions of mitochondrial diseases [2]. All pathogenic mtDNA mutations result in reduced ATP
production as a primary phenotype. However, the resultant disease phenotypes are diverse,
and the mechanisms of expression of disease phenotypes are not well known. The most effec-
tive approach to elucidate these mechanisms is generation and analysis of animal models of
disease, in which an animal harbors a mutation that corresponds to a disease of interest. How-
ever, because techniques for artificial manipulation and mutagenesis of mtDNA are not well
established, generating animal models of disease corresponding to each human mitochondrial
disease phenotype is very difficult.
Instead of using artificial mutagenesis, we have previously concentrated native mutations
that exist in mouse cell lines at a very low frequency, and we then generated some mouse mod-
els of mitochondrial diseases [3–6]. However, this approach limits the array of mtDNA muta-
tions as a source of mouse models of disease.
To overcome this difficulty, we focused on the mtDNA of “mutator mice”. Mutator mice
have been generated by disrupting the proofread function of DNA polymerase γ (PolG), the
only DNA polymerase for mtDNA [7, 8]. These mice accumulate random mtDNA mutations
attributed to replication errors with age. Such diverse random mtDNA mutations possibly
comprise mutations corresponding to certain human pathogenic mutations or novel patho-
genic mutations. Hence, mtDNA of mutator mice is an attractive starting material for explor-
ing pathogenic mtDNA mutations. However, the research group that created the mutator
mice reported a strong elimination of non-synonymous changes in protein-coding genes and
loss of variation of mutations in subsequent generations after crossing a mutator female with a
wild-type male [9]. If the selective pressure that eliminates harmful mutations is operational in
these mice, it would be difficult to concentrate certain pathogenic mtDNA mutations in
mouse by repeated crossing.
To address this challenge, we conceived an idea of using a cultured cell line as a research
tool. For example, although A3243G, the most frequent pathogenic mutation in mtDNA in
human, is observed only as a heteroplasmy (mixture of mutant and normal mtDNA) in
patients [10], it can exist as a homoplasmy (pure mutant mtDNA) in a cultured cell line [11].
This behavior is also common for other pathogenic mtDNA mutations. Furthermore, while
mouse or human lacking mtDNA cannot exist, mtDNA-less cells (ρ0 cells) can be established
and maintained in nutrient-rich medium supplemented with pyruvate and uridine [12, 13].
These observations suggest that cultured cell lines are resistant to severe respiration defects,
and show higher tolerance to harmful pathogenic mtDNA than cells in tissue. If that indeed is
the case, it should be possible to concentrate pathogenic mtDNA mutations using a cell line
harboring mtDNA derived from mutator mouse.
In the current study, we established a transmitochondrial cytoplasmic hybrid (cybrid) cell
line that harbors mtDNA containing random mutations by introducing platelet mtDNA from
mutator mouse into mouse ρ0 cells. By evaluating respiratory function and the mtDNA
sequence, we investigated whether mtDNA molecules containing random mutations might
serve as a starting material for the generation of novel mouse models of disease. Further, we
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evaluated the difference in mtDNA mutation tolerance between mouse tissue and a cultured
cell line, and the potential mechanisms that link respiration defects and random mtDNA
mutations.
Materials and methods
Cells and cell culture
B82 is a fibrosarcoma cell line (ECACC 08062522) derived from the L929 fibroblast line estab-
lished from C3H/An mouse. B82, ρ0B82 [13], and cybrids were grown at 37˚C with 5% CO2 in
RPMI 1640 medium (Nissui, Tokyo, Japan) containing 10% FBS (Sigma-Aldrich, St. Louis,
MO), uridine (50 mg/mL), and pyruvate (0.1 mg/mL). All experiments were performed in
accordance with the institutional guidelines.
Mice
The control C57BL/6J mouse was purchased from a breeder (CLEA Japan, Tokyo, Japan). The
mutator mouse line with C57BL/6J nuclear background was generated in our previous study
[14]. All animal care and use were approved by the Institutional Animal Care and Use Com-
mittee of the University of Tsukuba.
Generation of transmitochondrial cybrids
As mtDNA donors, 10-week-old male C57BL/6J mouse and 10-month-old male PolGmut/mut
mutator mouse were used. Blood samples (approximately 1 mL) were taken from each mouse
under anesthesia and then centrifuged at 300 × g for 5 min. The collected platelet-rich superna-
tant was combined with 1 × 104 ρ0B82 cells, and fused using the polyethylene glycol (PEG
1,500, Roche, Basel, Switzerland) method. Unfused nuclear donor ρ0B82 cells were eliminated
by incubation in a selection medium lacking uridine and pyruvate. B82mtΔ cells have been
generated previously [3]. Detailed procedures for the generation of transmitochondrial cybrids
are described elsewhere [15]. The replacement of mtDNA in cybrids was confirmed by PCR-
restriction fragment length polymorphism. Briefly, to distinguish the polymorphism at posi-
tion 9,348 (G in C57BL/6J mouse and A in C3H/An mouse), mtDNA was purified using an
mtDNA extractor CT kit (Wako, Osaka, Japan), and the 9,320–9,479-bp region was amplified
by PCR. Forward primer 50-AGC ATG ATA CTG ACA TTT TGT AGA CcT-30 (lowercase
letter indicates the mismatch site) and reverse primer 50-GAT AAC AGT GTA CAG GTT
AAT TAC TCT CTT CTG-30 were used. Combination of the PCR-generated mismatch with
the specific polymorphism created a restriction site for Xsp I in C57BL/6J mtDNA, such that
Xsp I digestion generated 134-bp and 26-bp fragments, and an intact 160-bp amplicon in
C3H/An mtDNA. Cybrid cells were cultured for at least 2 months after fusion before mtDNA
sequence analysis.
Biochemical determination of respiratory enzyme activity
Mitochondrial fraction was prepared from homogenized cell lysates, and mitochondrial respi-
ratory complex activities were determined. To determine the activities of complexes I + III, II
+ III, and IV, NADH and oxidized cytochrome c, sodium succinate and oxidized cytochrome
c, and reduced cytochrome c were added as substrates, respectively. Reduction (I + III, II + III)
and oxidation (IV) of cytochrome c were detected as a change in sample absorbance at 550
nm. Mean reaction rates for B82mtB6 and B82mtPolGmut/mut cells were calculated, and are
reported as relative values, with B82mtB6 values considered to be 100%.
Transmitochondrial cybrid cells as “concentrators” of mtDNA mutations
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Cytochrome c oxidase (COX)/succinate dehydrogenase (SDH) staining
Cytochemical analysis of COX and SDH activity was performed as described previously [16],
using coverslips with growing cells.
Deep-sequence analysis of mtDNA
mtDNA was extracted from cybrid cells by using an mtDNA extractor CT kit (Wako), electro-
phoresed on agarose gel, and purified by using the FastGene Gel/PCR Extraction Kit (Nippon
Genetics, Tokyo, Japan). To compare the mtDNA populations between cybrids and parental
platelets, platelets were prepared from the littermate of each mtDNA-donor mouse as
described above at the same timing of the generation of cybrids, and mtDNA was extracted by
using a Gentra Puregene Tissue Kit (QIAGEN, Venlo, Netherlands). Purified mtDNA was
fragmented into approximately 100-bp fragments, and sequenced using HiSeq 2500 (Illumina,
San Diego, CA), with chrM of the UCSC mm10 (http://hgdownload.cse.ucsc.edu/goldenPath/
mm10/bigZips/chromFa.tar.gz) as a reference sequence. Mutations occurring at a frequency
over 1% were analyzed to determine their effect on the encoded amino acid, and to check
whether the mutation sites were homologous to sites of human pathogenic mtDNA mutation.
Alignments of nucleic acid and amino acid sequences from mouse and human were performed
for every gene and region using T-COFFEE (http://tcoffee.vital-it.ch/apps/tcoffee/do:regular).
Native polyacrylamide gel electrophoreses (PAGE)
The crude mitochondrial fraction was isolated from cybrid homogenates by centrifugation
(900 × g for 5 min). The supernatant was collected and re-centrifuged at 5,000 × g for 10 min.
Isolated mitochondria (1 mg/mL) were solubilized at 4˚C for 30 min with 1% digitonin in
buffer (20 mM bis-Tris, 0.1 M NaCl, and 10% glycerol, pH 7.0), and centrifuged at 100,000 × g
for 15 min. The resulting supernatants were subjected to electrophoresis. Electrophoresis was
conducted as described before[17] using NativePAGE 3–12% Bis-Tris Protein Gels (Thermo
Fisher Scientific, Waltham, MA). To detect respiratory complexes, proteins were transferred
to a polyvinylidene fluoride (PVDF) membrane (Thermo Fisher Scientific). The membrane
was blocked with 5% skim milk in TBS-T, and MitoProfile Total OXPHOS Blue Native WB
Antibody Cocktail (at 1:250, MS603, Mitosciences, Eugene, OR) was used as the primary anti-
body, following the manufacturer’s recommendations. Horseradish peroxidase-linked anti-
mouse IgG (at 1:3000, #7076, Cell Signaling Technology, Danvers, MA) was used as the sec-
ondary antibody, and incubated with ECL substrate (Thermo Fisher Scientific) in agreement
with the manufacturer’s guidelines. Detection was performed using the ImageQuant LAS4000
(GE Healthcare, Little Chalfont, UK). To evaluate in-gel complex I activity, gels were incubated
in assay buffer (2 mM Tris-HCl, 0.1 mg/mL NADH, and 2.5 mg/mL nitro blue tetrazolium
chloride (NTB), pH 7.4).
Quantification of proteins
Total protein was extracted from cybrids using the EzRIPA Lysis Kit (ATTO, Tokyo, Japan).
SDS-PAGE was performed using NuPAGE 4–12% Bis-Tris gels (Thermo Fisher Scientific)
and MOPS Running Buffer (Thermo Fisher Scientific). Then, the proteins were transferred to
PVDF membrane. After blocking with a PVDF Blocking Reagent (TOYOBO, Osaka, Japan),
membranes were incubated with the following primary antibodies: anti-NDUFA9 (ab14713,
Abcam, Cambridge, UK), anti-MT-ND1 (ab181848, Abcam), anti-SDHA (#11998, Cell Signal-
ing Technology), anti-COX IV (#4850, Cell Signaling Technology), anti-MT-COI (ab14705,
Abcam), anti-Hsp60 (#12165, Cell Signaling Technology), anti-mtHsp70 (#3593, Cell
Transmitochondrial cybrid cells as “concentrators” of mtDNA mutations
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Signaling Technology), anti-Tid1 (#4775, Cell Signaling Technology), anti-Lonp1 (NBP1-
81734, Novus Biologicals, Littleton, CO), and anti-α–Tubulin (T-5168, Sigma-Aldrich). All
primary antibodies described above were used at 1:1000 dilution. As the secondary antibodies,
horse radish peroxidase-linked anti-mouse IgG (at 1:3000, #7076, Cell Signaling Technology)
or anti-rabbit IgG (at 1:3000, #7074, Cell Signaling Technology) was used. The membranes
were then incubated with ECL substrate (Thermo Fisher Scientific). Signal detection and
quantification were performed using the ImageQuant LAS4000 (GE Healthcare) and Multi-
Gauge software (FUJIFILM, Tokyo, Japan).
Statistical analysis
The sample size of each test and statistical method used for data analysis are stated in each fig-
ure legend. Statistical analyses were conducted using GraphPad Prism 6.0 (GraphPad Soft-
ware, La Jolla, CA). P-value of less than 0.05 was considered to indicate statistically significant
differences between samples.
Results
Establishment of transmitochondrial cybrid cells harboring random
mtDNA mutations
Previously, based on the original papers by Trifunovic et al. [7] and Kujoth et al. [8], we have
introduced the D257A mutation into the PolG gene of C57BL/6J mouse and generated
mtDNA mutator mouse [14]. As the mtDNA donor, we used a 10-month-old male PolGmut/mut
mouse, a generation 8 offspring of PolG+/mut-to-PolG+/mut mating. Because successive genera-
tions of mice inherit maternal mtDNA mutations by germline transmission, it is thought that
they harbor more mtDNA mutations than generation 1 offspring [18]. A 10-week-old C57BL/
6J male mouse was used as a control. Platelets obtained from each mouse were fused with ρ0B82
cells [13], which are mtDNA-less cells from the B82 fibrosarcoma cell line derived from C3H/
An mouse. Thus, B82mtB6 and B82mtPolGmut/mut cybrids were established, accordingly (S1
Fig). Analysis of strain-specific mtDNA polymorphisms confirmed the replacement of C3H/
An-type mtDNA by C57BL/6J-type mtDNA (Fig 1A). Measurements of respiratory complex
activity revealed remarkable respiration defects in B82mtPolGmut/mut cells (Fig 1B). Further, spe-
cific staining confirmed severe COX (complex IV) deficiency in B82mtPolGmut/mut cells (Fig
1C). On the other hand, the staining indicated that the SDH (complex II) activity in
B82mtPolGmut/mut cells was rather up-regulated (Fig 1C). Thus, the reduced complex II + III
activity shown in Fig 1B appeared to stem from a defect in complex III, and not a defect in com-
plex II.
These observations indicated that the activities of respiratory complexes, except for com-
plex II, in cells harboring mtDNA derived from the mutator mouse were severely impaired,
and OXPHOS function was almost completely abolished in B82mtPolGmut/mut cells.
B82mtPolGmut/mut cells harbor various mtDNA mutations at high
frequency
We then extracted mtDNA molecules from each cybrid and platelets obtained from the litter-
mate of each mtDNA-donor mouse of the cybrids, and analyzed by deep-sequencing. More
than 2 million reads were analyzed. The average depth of coverage of the entire mtDNA
sequence was over 12,000× (Table 1). Mutation analysis data are shown in S1 (cybrids) and S2
(platelets) Tables. The mutation frequency per 10 kb is shown in Table 1 and Fig 2A. As indi-
cated in Table 1, Fig 2A and 2B, mtDNA molecules from B82mtPolGmut/mut cells harbored
Transmitochondrial cybrid cells as “concentrators” of mtDNA mutations
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Fig 1. Establishment of transmitochondrial cybrid cells and their characterization. (A) Genotyping of mtDNA by
PCR-restriction fragment length polymorphism confirmed the replacement of mtDNA in the constructed cybrids.
Compared with the C57BL/6J mouse, mtDNA of the C3H/An mouse (the source of B82 cells) harbors G9348A
polymorphism. Hence, the origin of mtDNA in the current study could be distinguished by detecting this strain-
specific polymorphism (see methods for details). (B) Relative respiratory complex activities. Data are presented as the
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approximately eight times more mutations than those of B82mtB6 control cells. The mutation
frequency was also higher than that of platelets obtained from a littermate of an mtDNA-
donor (Fig 2A and 2B). Mutations occurring at a frequency of at least 1% in cybrids and plate-
lets are shown in Fig 2C and 2D, respectively. Only seven mutations fulfilling this criterion
were identified in B82mtB6 cells, in comparison with 137 mutations in B82mtPolGmut/mut
cells. Regarding platelets, 11 and 48 mutations were found at more than 1% of frequency in B6
and PolGmut/mut mice, respectively. This indicated that B82mtPolGmut/mut cells harbored more
mutations that occurred at high frequency than the control cells and platelets of mutator mice.
Moreover, majority of the mutation rates of these 137 mutations were either approximately
5%, 10%, or 40% (Fig 2C). Notably, however, comparison of the diversity of mutations
revealed that platelets from PolGmut/mut mice harbored more diverse mutations than their
cybrids, B82mtPolGmut/mut cells (Fig 2E).
Among mutations occurring at a frequency of>1% in cybrid cells, mutations mapped to
protein-coding regions are listed in Table 2. Overall, 101 mutations were located in protein-
coding regions; of these, 68 were non-synonymous mutations (67.3%). Mutations in the
tRNA- or rRNA-coding, or non-coding regions are listed in Table 3. Among mutations listed
in Tables 2 and 3, we attempted to identify mutations homologous to human pathogenic
mtDNA mutations. Details of mutations occurring at homologous bases or affecting amino
acids homologous to those of human pathogenic mutations listed in MITOMAP (https://
mitomap.org), a human mitochondrial genome database, are shown in S3 Table.
Among mutations located in the protein-coding regions, no homologous mutations that
constituted exact matches at base level to human pathogenic mutations were identified. How-
ever, three mutations resulted in changes of a homologous amino acid because they affected
the same triplet codon as mutations in human. These mutations affected homologous amino
acid but their effects (specific amino acid changes) were different from those observed in
human disease cases (S3 Table). Therefore, although these three mutations were located at
sites homologous to those of human pathogenic mutations, their effects on the function or
structure of the encoded protein products were probably not homologous to human.
mean + S.D. ����P< 0.0001, according to the independent two-tailed t-test (n = 3). (C) COX/SDH staining of cybrid
cells. Cells with normal COX activity stain brown, whereas cells with defective respiration stain blue. The images are
representative of 3 replicates. Scale bar = 50 μm.
https://doi.org/10.1371/journal.pone.0213283.g001
Table 1. Overview of sequence analysis.
B82mt Platelets
B6 PolGmut/mut B6 PolGmut/mut
On-target read number 2,038,897 2,902,204 5,173,781 7,516,437
Depth average 12,442 17,701 31,565 45,824
Coverage rate >3× 100.00 100.00 100.00 100.00
>10× 100.00 100.00 100.00 100.00
>20× 100.00 100.00 100.00 100.00
>40× 99.99 100.00 100.00 100.00
Total analyzed bases 192,221,549 273,833,727 498,203,226 728,866,493
Total mutations� 59,960 686,532 81,320 1,018,148
Mutation frequency (bases/10 kb) 3.12 25.07 1.63 13.97
Mutation frequency for each base (%) 0.0307 0.2411 0.0165 0.1416
� The number of base substitutions and insertions/deletions.
https://doi.org/10.1371/journal.pone.0213283.t001
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Among mutations in the tRNA-coding regions, three mutations occurred at bases homolo-
gous to those observed in human disease cases. Since both sites and base changes (the before
and after status) corresponded to human cases, their effects on encoded products might be
analogous to those in human diseases.
Next, we explored mutations homologous to confirmed pathogenic mutations in human
mtDNA among mutations that occurred in the cybrids at a frequency below 1%. For all the con-
firmed pathogenic mutations listed in MITOMAP (last accessed: 17 December, 2018), whose
pathogenicity has been strongly suggested, we surveyed the mutation rate of homologous muta-
tions in the cybrids (S4 Table). As of December 2018, 83 confirmed pathogenic mutations were
listed in MITOMAP. The frequency of the most frequently occurring homologous mutations
was below 0.1%, indicating that these potential pathogenic mutations were contained at a very
low frequency. Considering the tRNALeu(UUR) gene, known as a hotspot of human pathogenic
mutations, the mutation rate of each base in B82mtB6 and B82mtPolGmut/mut cells was similar
(Fig 2F).
In summary, even though B82mtPolGmut/mut cells contained various mutations at a higher
frequency, not many mutations that occurred at a frequency of at least 1% were homologous
to human pathogenic mutations, with respect to both site and quality.
Abnormal respiratory complex formation in B82mtPolGmut/mut cells
Although B82mtPolGmut/mut cells harbored few mutations homologous to human pathogenic
mutations, they exhibited severe respiration defects. To determine the molecular mechanisms
underpinning these respiration defects, we analyzed mitochondrial proteins by clear native
PAGE [17] (Fig 3A). The experiment clearly demonstrated that complex I was dramatically
reduced and almost undetectable in B82mtPolGmut/mut cells. The reduction was more pro-
nounced therein than in B82mtΔ cells, a cybrid with mtDNA with a large-scale deletion
(ΔmtDNA) [3], which lacking genes encoding multiple subunits of complex I (Fig 3A). Con-
sidering the possibility of formation of a functional complex I in the absence of NDUFA9, the
subunit used for the detection of complex I in clear native PAGE, we then evaluated the in-gel
activity of complex I (Fig 3B). The activity of complex I was almost completely undetectable in
this assay. On the other hand, complex II, all of which components are encoded by nuclear
DNA, was not affected; the amounts of complex III and V were slightly reduced; and the
mobility of complex IV exhibited a molecular mass shift to lower masses in B82mtPolGmut/mut
cells (Fig 3A).
We next evaluated the relative abundances of the subunits from complexes I and IV (the
most affected complexes), and II (the unaffected complex). The data indicated that in addition
to the changed abundances of mtDNA-encoded subunits, the abundances of nuclear DNA-
Fig 2. Deep-sequence analysis of the established cybrid cells. (A) Mutation frequency (per 10 kb) in each cybrid and
platelet. The actual values are provided in Table 1. (B) Mutation frequency of each base in the entire mtDNA. Data are
presented as the mean + S.E. ����P< 0.0001 by 1-way ANOVA. (n = 16,299). The actual values are provided in
Table 1. Among all the detected mutations, only mutations occurring at a frequency of at least 1% in cybrid cells (C)
and platelets (D) are shown. Green, yellow, and red bands indicate mutation ranges of 4–6%, 8–12%, and 30–50%,
respectively. Blue band in (C) shows the tRNALeu(UUR) gene region. Rep. Ori., replication origin. (E) Comparison of
diversity of mtDNA mutations. All types of substitution and insertion/deletion mutations were quantified
independently, and total sums are shown (e.g., in the case of a base A mutated as A>G, A> T, and AinsAA,
mutations for this base would be counted as 3). Note that platelets of PolGmut/mut mice harbored more diverse
mutations than B82mtPolGmut/mut cells, despite a lower mutation frequency than that of B82mtPolGmut/mut cells. (F)
Mutation rates for each base in the tRNALeu(UUR) gene in cybrid cells. Data are presented as the mean + S.D. P-value
calculated by using paired two-tailed t-test is indicated (n = 75).
https://doi.org/10.1371/journal.pone.0213283.g002
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Table 2. Mutations in protein-coding regions occurring at a frequency above 1% in cybrid cells.
Gene N.P. Ref.� Mutation frequency Most frequent change Amino acid Non-syn?�� Human N.P.
B82mtB6 B82mt
PolGmut/mut
Posi-
tion
Change
Nd1 2,934 C 0.044 44.522 >T 62 R > C Yes 3,490
3,010 T 0.014 41.861 >C 87 V > A Yes 3,566
3,181 T 0.015 4.904 >C 144 V > A Yes 3,737
3,328 C 0.054 47.286 >T 193 T > M Yes 3,884
3,340 C 0.055 4.646 >T 197 P > L Yes 3,896
3,373 T 0.015 10.176 >A 208 V > E Yes 3,929
Nd2 3,953 T 0.029 37.104 >C 14 F > L Yes 4,509
3,997 A 0.037 37.327 DEL A 28 FrShift Yes 4,553
4,733 A 0.007 32.312 >T 274 N > Y Yes 5,289
4,826 T 0.030 33.102 >C 305 F > L Yes 5,382
4,922 C 0.059 44.905 >A 337 L > M Yes 5,478
CoI 5,400 T 0.051 41.018 >C 25 W > R Yes 5,976
5,402 A 0.036 5.167 >G 25 W > W 5,978
5,539 T 0.014 10.745 >C 71 M > T Yes 6,115
5,630 T 0.153 40.322 >C 101 S > S 6,206
5,676 A 0.024 46.383 >C 117 M > L Yes 6,252
5,697 A 0.000 39.583 >G 124 T > A Yes 6,273
5,706 A 0.023 4.922 >G 127 T > A Yes 6,282
5,741 T 0.053 41.141 >C 138 H > H 6,317
5,830 T 0.022 5.124 >C 168 I > T Yes 6,406
5,932 T 0.044 42.419 >C 202 L > P Yes 6,508
6,038 C 0.014 30.930 >T 237 F > F 6,614
6,086 T 0.014 30.695 >C 253 I > I 6,662
6,149 A 0.034 31.097 >G 274 V > V 6,725
6,221 T 0.036 31.465 >C 298 D > D 6,797
6,269 T 0.037 10.860 >C 314 I > I 6,845
6,311 C 0.107 31.338 >T 328 H > H 6,887
6,534 T 0.029 4.620 >C 403 F > S Yes 7,110
6,633 A 0.011 42.986 >G 436 M > V Yes 7,209
6,666 T 0.011 10.908 >C 447 Y > H Yes 7,242
6,765 C 0.026 36.510 >T 480 R > W Yes 7,341
6,861 A 0.014 35.214 >T 512 K > Stop Yes 7,437
CoII 7,079 T 0.027 35.953 >C 23 F > L Yes 7,652
7,136 A 0.055 44.564 >G 42 I > V Yes 7,709
7,246 C 0.093 43.508 >G 78 L > L 7,819
7,417 G 0.026 43.893 >A 135 L > L 7,990
Atp8 7,830 T 0.040 45.416 >C 22 I > T Yes 8,430
Atp6 7,981 A 0.013 33.690 >G 19 I > V Yes 8,581
8,002 T 0.013 44.333 >C 26 F > L Yes 8,602
8,004 T 0.027 10.520 >C 26 F > F 8,604
8,017 T 0.041 34.119 >C 31 F > L Yes 8,617
8,278 C 0.026 10.818 >T 118 R > W Yes 8,878
Atp6 /CoIII 8,607 A 0.026 9.648 >G 227/1 Stop > Stop/M > M 9,207
(Continued)
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Table 2. (Continued)
Gene N.P. Ref.� Mutation frequency Most frequent change Amino acid Non-syn?�� Human N.P.
B82mtB6 B82mt
PolGmut/mut
Posi-
tion
Change
CoIII 8,676 G 0.065 99.991 >A 24 A > T Yes 9,276
8,875 A 0.000 4.783 >G 90 E > G Yes 9,475
8,945 A 0.000 10.046 >G 113 G > G 9,545
8,996 A 0.027 9.081 >C 130 P > P 9,596
9,008 T 0.028 9.633 >G 134 T > T 9,608
9,106 T 0.013 43.745 >C 167 I > T Yes 9,706
9,292 C 0.196 45.462 >T 229 S > L Yes 9,892
Nd3 9,460 T 1.124 0.010 DEL T 1 FrShift Yes 10,060
9,461 T 53.846 0.015 >C 1 M > M 10,061
9,632 A 0.024 9.456 >G 58 V > V 10,232
9,638 T 0.000 9.529 >C 60 I > I 10,238
Nd4L 9,977 A 0.034 4.721 >G 34 E > G Yes 10,570
10,022 T 0.116 43.147 >A 49 L > Q Yes 10,615
10,060 A 0.000 4.839 >G 62 T > A Yes 10,653
10,072 T 0.016 10.906 >C 66 F > L Yes 10,665
Nd4 10,342 A 0.014 42.844 >G 59 D > G Yes 10,935
10,596 A 0.000 10.864 >G 144 N > D Yes 11,189
10,610 T 0.000 10.638 >C 148 Y > Y 11,203
10,786 T 0.021 4.693 >C 207 M > T Yes 11,379
10,903 T 0.020 40.613 >C 246 I > T Yes 11,496
11,227 T 0.030 10.145 >C 354 L > P Yes 11,820
11,283 A 0.035 31.306 >G 373 I > V Yes 11,876
11,323 T 0.020 30.334 >C 386 F > S Yes 11,916
11,489 A 0.014 43.339 >G 441 M > M 12,082
11,518 C 0.043 33.252 >A 451 P > Q Yes 12,111
Nd5 12,000 A 0.014 31.510 >G 87 I > V Yes 12,595
12,160 T 0.037 4.849 >C 140 L > P Yes 12,755
12,213 T 0.022 10.250 >C 158 W > R Yes 12,808
12,236 T 0.030 31.976 >C 165 N > N 12,831
12,414 G 20.418 0.039 >A 225 A > T Yes 13,009
12,440 A 0.008 9.935 >G 233 L > L 13,035
12,462 A 0.016 31.829 >G 241 T > A Yes 13,057
12,510 A 0.008 9.750 >G 257 I > V Yes 13,105
12,529 T 0.016 33.597 >C 263 F > S Yes 13,124
12,572 A 0.015 10.042 >G 277 M > M 13,167
12,597 T 0.022 4.870 >C 286 L > L 13,192
12,765 T 0.029 41.219 >A 342 C > S Yes 13,360
12,996 A 0.029 46.237 >G 419 T > A Yes 13,591
13,052 T 1.586 32.567 INS C 437 FrShift Yes 13,647
13,233 T 0.022 45.182 >C 498 F > L Yes 13,828
13,305 T 0.007 4.275 >C 522 F > L Yes 13,900
13,398 C 0.069 99.940 >T 553 L > L 13,993
13,442 A 0.038 42.040 >G 567 S > S 14,037
13,497 T 0.014 4.727 >C 586 L > L 14,092
(Continued)
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encoded subunits of complexes I and IV were substantially altered (Fig 3C). By contrast, the
abundances of complex II subunit were not significantly affected.
Since abnormal complex formation and unbalanced subunit levels were observed, we then
examined the expression of representative chaperons and a protease, to determine whether the
mitochondrial protein quality control system was experiencing stress. Although the expression
of Hsp60 (also known as Hspd1), a major mitochondrial chaperon [19], was not significantly
altered, the expression of mtHsp70 (also known as Grp75, Mortalin, or Hspa9), a key factor for
protein folding in the matrix [20] and for protein import from the cytosol to the mitochon-
drion [21], was slightly up-regulated (Fig 3D). The expression of both, the long and short iso-
forms of Tid1 (also known as Dnaja3) [22], a co-chaperone for mtHsp70 and activator of its
ATPase activity [23, 24], was dramatically increased. The expression of mitochondrial serine
protease Lonp1 (also known as Prss15) was similarly elevated (Fig 3D).
Discussion
In the current study, we investigated the possibility of using specific cybrids for mtDNA muta-
tion accumulation, as a starting point for the investigation of links between specific mutations
and disease. Deep-sequence analysis of the generated cybrid cells revealed that they harbored
various mtDNA mutations at a higher frequency. Although the reported mutation rates in tis-
sues of mutator mice depend on the methods or materials used (tissue type, animal age, and
nuclear background used), they range, roughly, from several to dozen bases per 10 kb [7, 8, 18,
25]. In addition, we determined the mutation rate in platelets. The rate of 13.97 mutations per
10 kb (Table 1 and Fig 2A) was consistent with previous reports of other tissues. In contrast,
the mutation rate in B82mtPolGmut/mut cells was 25.07 bases per 10 kb over all mtDNA mole-
cules (Table 1), which is several times higher than that reported in tissues and platelet [7, 8, 18,
25]. However, even more striking than the overall average mutation rate, several specific muta-
tions accumulated at a high frequency in the generated cybrid cells. The frequency of
Table 2. (Continued)
Gene N.P. Ref.� Mutation frequency Most frequent change Amino acid Non-syn?�� Human N.P.
B82mtB6 B82mt
PolGmut/mut
Posi-
tion
Change
Nd6 13,654 A 0.024 46.144 >T 139 I > M Yes 14,254
13,948 T 0.032 35.247 >C 41 L > L 14,551
Cytb 14,148 A 0.021 4.849 >G 2 T > A Yes 14,750
14,151 A 0.021 42.171 >G 3 N > D Yes 14,753
14,207 A 0.038 40.587 >G 21 L > L 14,809
14,345 A 0.036 33.216 >T 67 T > T 14,947
14,574 A 0.022 31.714 >G 144 T > A Yes 15,176
14,745 C 0.070 33.947 >T 201 H > Y Yes 15,347
14,777 A 0.036 10.641 >G 211 L > L 15,379
14,797 T 0.022 44.566 >C 218 I > T Yes 15,399
14,802 T 0.007 5.513 >C 220 F > L Yes 15,404
15,030 T 0.022 8.968 >C 296 L > L 15,632
15,145 T 0.008 4.545 >C 334 I > T Yes 15,747
15,241 T 0.014 9.047 >C 366 M > T Yes 15,843
� Reference sequence.
�� “Yes” if the mutation is a non-synonymous mutation.
https://doi.org/10.1371/journal.pone.0213283.t002
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Table 3. Mutations in rRNA and tRNA, or non-coding regions occurring at a frequency above 1% in cybrid cells.
Gene N.P. Ref� Mutation frequency Most frequent change Human N.P.
B82mt B82mt
B6 PolGmut/mut
tRNA-Phe 45 A 0.023 11.442 >G 623
12S rRNA 88 T 0.037 40.033 >C 667
177 G 0.045 45.691 >A 754
273 A 0.030 4.530 >C 852
816 A 0.089 99.983 >T 1,392
843 A 0.029 30.641 >G 1,420
tRNA-Val 1,033 A 0.015 31.182 >G 1,610
16S rRNA 1,144 T 0.007 10.113 >C 1,720
1,218 A 0.007 9.562 >G 1,790
1,328 A 0.015 4.820 >G 1,900
1,373 A 0.053 39.642 >G 1,945
1,381 A 0.044 44.471 >G 1,952
1,551 A 0.007 38.831 >G 2,123
1,795 A 0.028 10.260 >G 2,363
1,819 C 0.074 46.556 >T 2,386
1,935 T 0.023 9.536 >C 2,498
2,215 G 0.023 31.925 >A 2,776
2,468 T 0.069 43.184 >C 3,026
2,555 T 0.022 4.398 >C 3,114
2,620 T 0.015 9.891 >C 3,176
tRNA-Ile 3,747 T 0.014 40.502 >C 4,304
tRNA-Gln 3,777 A 0.029 41.356 >G 4,334
3,807 T 0.023 37.029 >A 4,364
tRNA-Met 3,852 T 0.023 34.223 >C 4,409
3,909 T 0.015 4.964 >A 4,465
tRNA-Trp 4,963 A 0.021 33.681 >G 5,525
4,980 T 0.063 5.725 >C 5,543
tRNA-Ala 5,019 A 0.034 43.497 >G 5,588
tRNA-Asn 5,137 A 0.016 31.232 >T 5,705
Rep-Ori�� 5,171 G 3.898 64.944 INS A 5,741
5,172 A 3.161 0.867 DEL A 5,742
tRNA-Ser(UCN) 6,889 A 0.015 11.716 >G 7,465
6,926 A 0.040 44.828 >G 7,502
tRNA-Asp 6,950 A 0.027 5.414 >G 7,526
tRNA-Gly 9,399 A 0.022 4.793 >G 9,999
tRNA-His 11,574 T 0.034 48.750 >C 12,167
tRNA-Leu(CUN) 11,696 T 0.014 41.697 >C 12,291
D-loop 15,588 C 99.931 0.020 >T 16,290
15,651 T 0.030 4.484 >C 16,362
15,974 A 0.024 9.471 >G 128
16,176 T 0.022 10.159 >C 405
� Reference sequence.
�� Replication origin.
https://doi.org/10.1371/journal.pone.0213283.t003
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occurrence of many mutations was over 40% in B82mtPolGmut/mut cells (Fig 2C). These muta-
tion frequencies were higher than any other rates for tissues of mutator mouse, such as the
brain and heart [26], skeletal muscle [27], liver [28], and platelets reported here (Fig 2D).
Mutations that occur at such high rates appear to be either fixed in mice over generations via
the germline [18], or increase by random segregation [29] and/or clonal expansion [30, 31]
after introduction into cultured cells.
Furthermore, most mutations occurring at a frequency above 1% in B82mtPolGmut/mut cells
converged around either approximately 5%, 10%, or 40% (Fig 2C). If each mutation rate
increases or decreases randomly, such convergence would not occur. Thus, it appeared that
the converged status was stable, and that some mechanisms might exists that maintain it. We
suggest two hypothetical mechanisms. One involves the severity of pathogenesis of each muta-
tion. Upper limits of mutation rates might exist in cells, depending on the mutation pathoge-
nicity, split into roughly three stages. However, approximately 40% of mutations contained
both synonymous and non-synonymous mutations, and mutations occurred at sites homolo-
gous to those of human pathogenic mutations were also contained. Approximately 5% of
mutations also contained all of these mutations similarly. Thus, it cannot be simply assumed
that pathogenicity of approximately 40% of mutations was low and that of approximately
5% of mutations was high. According to the other hypothetical mechanism, mutations that
converged at similar mutation rates are linked on the same mtDNA molecule, with each
mtDNA molecule containing approximately 5%, 10%, or 40% of the total mtDNA pool in
B82mtPolGmut/mut cells. In support of this hypothesis, it should be assumed that a heavily
biased clonal expansion has occurred. In fact, it has been reported that in mutator mouse, tis-
sue cells exhibiting respiration defects accumulate certain non-synonymous mutations at high
frequency [16]. Further, clonal expansion was also observed after some drug treatments [32]
or in tumor cells [33]. Taking into account these previous reports and the fact that the cybrids
are tumor cells derived from fibrosarcoma, the possibility that clonal expansion plays a role in
the convergence of mutation rates observed in B82mtPolGmut/mut cells is conceivable. We thus
developed a hypothesis related to the high mutation frequency following clonal expansion:
Because platelets are very small cells, not all mutations we revealed in S2 Table would be con-
tained in one or even a small number of platelets that fuse with ρ0B82 cells, indicating that a
subpopulation of mutant mtDNAs would be introduced into ρ0B82 cells through cell fusion.
Considering that B82 cells are considerably larger than platelets, the small number of mtDNAs
introduced would replicate and increase in number. It can be considered that this process is
similar to that of mtDNA bottlenecking during oocyte development. Previously, it was pro-
posed that biased replication of a subpopulation of mtDNAs results in the genetic bottleneck
of mtDNA [34]. This biased replication could occur in the generated cybrid cells and induces
the clonal expansion of some specific mtDNA molecules without any selection, as ρ0B82 cells
can harbor severe pathogenicities induced by predominant accumulation of pathogenic
mtDNAs, owing to their respiration defect resistance (S2 Fig). In animal tissues or organs, no
mtDNA-less cells are present except for terminally differentiated erythrocytes, and mitochon-
drial respiration-null cells would not survive. In contrast, ρ0B82 cells can survive without
mtDNA and adapt to and/or resist a mitochondrial respiration-free environment. We consider
that this strong resistance to respiration defects and biased replication of mtDNA enable
Fig 3. Abnormal respiratory complex formation in B82mtPolGmut/mut cells. (A) Detection of the formed respiratory complexes by clear native
PAGE. (B) In-gel evaluation of the activity of complex I. (C) Western blot analysis of the subunits of each respiratory complex (left) and band intensity
quantification (right). Left: N and M refer to the nuclear DNA-encoded and mtDNA-encoded subunits, respectively. (D) Western blot analysis of
mitochondrial chaperons, co-chaperons, and protease (left), and band intensity quantification (right). Data are presented as the mean + S.D.
�P< 0.05, ��P< 0.01, ���P< 0.001, ����P< 0.0001, according to an independent two-tailed t-test (n = 3).
https://doi.org/10.1371/journal.pone.0213283.g003
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pathogenic mtDNA mutations to accumulate at a high frequency. The higher frequency but
lower diversity of mtDNA mutations in our cybrid cells compared with parental platelets (Fig
2A–2E) also supports our hypothesis related to biased replication of a subpopulation of
mtDNA in parental platelets (S2 Fig).
At the same time, notably, whereas B82mtPolGmut/mut cells harbored various mutations,
including non-synonymous mutations, at a high frequency, almost no mutations homologous
to human pathogenic mutations were observed (S3 Table). When the entire mtDNA molecules
were compared, it was apparent that the mtDNA mutation rate in B82mtPolGmut/mut cells was
significantly higher than that in B82mtB6 cells (Table 1 and Fig 2A and 2B). However, when
the comparison region was restricted to the tRNALeu(UUR) gene, the hotspot of human patho-
genic mtDNA mutations, the mutation rates for each base in B82mtB6 and B82mtPolGmut/mut
cells were not significantly different (Fig 2E), indicating that the frequency of mutations in this
region was not increased by PolG mutation. Focusing on a more specific site, the A2689G
mutation, a mutation homologous to human A3243G mutation, which is the most frequent
mutation observed in human mitochondrial diseases, no such reads were detected among
13,997 reads in B82mtB6. Even in the B82mtPolGmut/mut cells, only two such reads were identi-
fied among 19,201 reads (S1 Table). These observations suggested that mutation hotspot
regions in human mtDNA and hotspot regions induced by PolGmut/mut in mouse mtDNA are
dissimilar.
Although we did not identify mutations homologous to confirmed human pathogenic
mutations that occurred at a high frequency in B82mtPolGmut/mut cells, these cells exhibited
severe respiration defects (Fig 1B and 1C). Abnormal respiratory complex formation appeared
to be involved in these respiration defects. In the most affected complex I, whereas drastic
changes in the expression of complex subunits were observed, not all of them were completely
lost (Fig 3C). However, the formation and function of complex I were almost entirely abol-
ished (Fig 3A and 3B). Although abnormal respiratory complex formation has been reported
in mutator mouse tissues [35], almost complete disappearance of complex I observed in the
cybrid cells in the current study was much more severe than that observed in mouse tissues.
These exceedingly severe abnormalities were not lethal to the cultured cell line, in contrast
with mouse tissues or organs. Furthermore, the increased expression of chaperons, co-chaper-
ons, and a protease in the B82mtPolGmut/mut cells (Fig 3D) probably reflected accelerated pro-
tein degradation by proteases because of the shortened lifespan of respiratory complexes
incorporating abnormal subunits, and activated protein transport from the cytosol to the mito-
chondrial matrix to recruit subunits to replace the ones that had been degraded.
Analyses presented in the current study revealed that a cultured cell line can indeed harbor
various mtDNA mutations that occur at a high frequency, and can be maintained regardless of
the induced severe respiration defects, which are not viable in mouse tissues. On the other
hand, despite the fact that the generated cybrids harbored various mutations, few mutations
homologous to human pathogenic mutations were identified. Therefore, it might be challeng-
ing to use the generated cybrids as a source of mutations for the development of novel mouse
models of specific human diseases. However, cultured cells that harbor frequently occurring
harmful mutations are very useful tools for concentrating mtDNA mutations. Some of the
mutations identified in the current study might be pathogenic mutations that are common
predisposing factors for human diseases, even if the mutation sites are not entirely consistent
with human. Importantly, since ρ0B82 cells, the mtDNA recipient cells used in this study,
express wildtype PolG, accumulation of de novo mtDNA mutations rarely occurred in re-pop-
ulated mtDNA molecules after fusion. Our sequence analysis suggested that at least a portion
of re-populated mtDNAs were clonally expanded from the small population of introduced
mtDNAs (S2 Fig). Many mutations were linked on the same mtDNA molecule, and as a result,
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the effects of individual mutations in this condition in our current cybrid cells cannot be evalu-
ated; however, controlling the mutation load in parental platelets by generation, age, or
mtDNA refresh through mating of male mutator mice with female wild-type mice [18], may
enable control of mtDNA populations in established cybrid cells. When the small population
of introduced mtDNAs harbor useful mutations, the mutations can be concentrated in gener-
ated cybrid at levels that would be fatal in mouse tissue. Ultimately, these mutations can be
introduced into mouse at appropriate mutation rate [36], and novel mouse models of
mtDNA-based diseases can be generated. The generated mouse models may facilitate under-
standing of the mechanism of diverse disease phenotypes due to mtDNA mutations.
Supporting information
S1 Fig. Scheme for the establishment of transmitochondrial cybrids. For the experiment,
ρ0B82 cells and platelets obtained from mice were used as mtDNA recipients and donors,
respectively. Recipient and donor cells were fused using the polyethylene glycol method, and
the resultant transmitochondrial cybrids were selected by culturing in a selective medium (see
Materials and Methods for details).
(EPS)
S2 Fig. Schematic illustration of the predicted process by which mtDNA mutations are
concentrated at high frequency. The platelets contain diverse mtDNA mutations as a popula-
tion, but “real parental” platelets, which fuse with ρ0B82 cells, harbor only a portion thereof.
Because ρ0B82 cells are larger than platelets, the introduced mtDNA molecules replicate and
increase in number after cell fusion. Because of the biased replication of mtDNA, a subpopula-
tion of mtDNA molecules dominantly increases, and mutations on those molecules also
increase simultaneously. Although accumulation of various mtDNA mutations at high fre-
quency induces severe respiration defects, the generated cybrid cells can survive and prolifer-
ate because of their resistance to the mitochondrial respiration-null condition, which was
acquired during the ρ0 state. As a result, a subpopulation of mutations in the parental platelets
is concentrated, resulting in a higher mutation frequency, but the diversity of mutations is
lower than that of parental platelets.
(EPS)
S1 Table. Mutation analysis of cybrid cells.
(XLSX)
S2 Table. Mutation analysis of platelets.
(XLSX)
S3 Table. Mutations homologous to human pathogenic mutations occurring at a frequency
above 1% in B82mtPolGmut/mut cybrid cells.
(XLSX)
S4 Table. Mutations homologous to human pathogenic mutations occurring at a frequency
under 1% in B82mtPolGmut/mut cybrid cells.
(XLSX)
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